enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Morgan Stanley Doubles Vir Biotechnology Price Forecast ...

   www.aol.com/morgan-stanley-doubles-vir...

   On Wednesday, Vir Biotechnology, Inc. (NASDAQ:VIR) presented initial Phase 1 data from two of its dual-masked T-cell engagers (TCEs): VIR-5818, which targets a variety of HER2-expressing solid ...

3. What's Going On With Liver Disease Focused Vir Biotechnology ...

   www.aol.com/finance/whats-going-liver-disease...

   On Friday, Vir Biotechnology, Inc. (NASDAQ:VIR) announced end-of-treatment data from Part B of the MARCH Phase 2 study evaluating combinations of tobevibart and elebsiran, with or without ...

4. Why Is Infectious Disease-Focused Vir Biotechnology Stock ...

   www.aol.com/finance/why-infectious-disease...

   On Wednesday, Vir Biotechnology Inc (NASDAQ:VIR) announced new preliminary data from its Phase 2 SOLSTICE hepatitis delta clinical trial evaluating tobevibart and elebsiran for chronic hepatitis ...

5. Vir Biotech slumps to over 3-year low as flu prevention ... - AOL

   www.aol.com/news/vir-biotech-slumps-over-3...

   News. Science & Tech. Shopping. Sports. Weather. 24/7 Help. For premium support please call: ... Vir Biotech slumps to over 3-year low as flu prevention therapy fails trial. July 20, 2023 at 12:37 PM

6. Time To Worry? Analysts Just Downgraded Their Vir ... - AOL

   www.aol.com/news/time-worry-analysts-just...

   The analysts covering Vir Biotechnology, Inc. ( NASDAQ:VIR ) delivered a dose of negativity to shareholders today, by...

7. Vir Biotechnology, Inc. (VIR) Soars 15.1%: Is Further Upside ...

   www.aol.com/news/vir-biotechnology-inc-vir-soars...

   Vir Biotechnology, Inc. (VIR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the ...

8. This Hepatitis Stock Has 'Multiple Paths To Value Creation ...

   www.aol.com/news/hepatitis-stock-multiple-paths...

   SVB Leerink initiated coverage on Vir Biotechnology Inc (NASDAQ: VIR) with an Outperform rating and a price target of $40, with an investment thesis based on: With multiple clinic programs, Vir is ...

9. Biotech Stock Roundup: VIR Down on Regulatory News, BMY ... - AOL

   www.aol.com/news/biotech-stock-roundup-vir-down...

   For premium support please call: 800-290-4726 more ways to reach us